Open AccessRilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
Author(s) -
Lourdes Anta,
Josep M Llibre,
Eva Poveda,
José Luis Santiago Blanco,
Marta Álvarez,
María Jesús Pérez-Elías,
Antonio Aguilera,
Estrella Caballero,
Vincent Soriano,
Carmen de Mendoza
Publication year - 2013
Publication title -
aids
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283584500
Subject(s) - rilpivirine , etravirine , efavirenz , nevirapine , virology , reverse transcriptase inhibitor , reverse transcriptase , drug resistance , medicine , human immunodeficiency virus (hiv) , pharmacology , biology , antiretroviral therapy , viral load , polymerase chain reaction , microbiology and biotechnology , gene , genetics
Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs.